(Q44820755)

6 December 2017

Fracture risk remains reduced one year after discontinuation of risedronate (English)

1 reference

6 December 2017

1 reference

5

1 reference

6 December 2017

N B Watts

1

1 reference

6 December 2017

A Chines

2

1 reference

6 December 2017

W P Olszynski

3

1 reference

6 December 2017

C D McKeever

4

1 reference

6 December 2017

X Zhou

6

1 reference

6 December 2017

A Grauer

7

1 reference

6 December 2017

language of work or name

English

0 references

publication date

16 October 2007

1 reference

Osteoporosis International

6 December 2017

1 reference

6 December 2017

19

1 reference

6 December 2017

3

1 reference

6 December 2017

365-372

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-007-0460-7

6 December 2017

0 references

cites work

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-007-0460-7

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-007-0460-7

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

21 January 2018

1 reference

12 December 2020

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

12 December 2020

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

1 reference

12 December 2020

Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

1 reference

12 December 2020

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover

1 reference

12 December 2020

Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography

1 reference

12 December 2020

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography

1 reference

12 December 2020

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

1 reference

12 December 2020

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

1 reference

12 December 2020

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

12 December 2020

Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing

1 reference

12 December 2020

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

1 reference

12 December 2020

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

12 December 2020

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Efficacy of risedronate on clinical vertebral fractures within six months.

1 reference

12 December 2020

Osteoporosis prevention, diagnosis, and therapy

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

12 December 2020

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

1 reference

12 December 2020

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

12 December 2020

10.1007/S00198-007-0460-7

Identifiers

DOI

1 reference

6 December 2017

1 reference